Preclinical Developments

BGP-15 has been extensively investigated in preclinical models of diseases commonly related to targeted mechanisms of the compound. The following table summarizes preclinical studies on BGP-15 in therapeutic indications in addition to human data generated in diabetes studies.

Cardio-protection

Atrial fibrillation/heart failure model in mouse, ischemia-reoxygenation in rat, hypertension induced heart failure in rat, imatinib-induced cardiotoxicity in rat, atrial fibrillation in drosophila melanogaster.

Protection of muscle loss

ICU treatment related muscle loss in rat and pig; inactivation and nerve transection induced muscle atrophy in mouse and rat.

Duchenne muscular dystrophy

Relevant knock out mouse models.